ABSTRACT
Objective Identify characteristics of persons who inject drugs living with HIV (PWID-LWH) associated with greater assisted partner services (APS) efficiency in identifying partners in need of HIV care and treatment services.
Design Prospective cohort study
Methods PWID-LWH (index participants) were enrolled and asked to provide contact information for sexual and injecting partners who were traced and offered HIV testing. APS efficiency was assessed by the number of indexes needed to interview (NNTI) to find one additional partner who was unaware of their HIV status or not on ART. We defined index participant characteristics associated with greater efficiency, defined as lower NNTIs.
Results Among 783 indexes, the NNTI to identify one partner unaware of their HIV status was 7.1 and to identify one HIV-positive partner not on ART (regardless of status awareness) was 4.1. APS was provided to 977 partners and was more efficient in identifying partners who were not on ART (n=201) among indexes who were female (n=381, 49%; NNTI=2.9 vs. 5.7, p<0.001), unaware of their HIV status (n=74, 9.5%; NNTI=2.2 vs. 4.2, p=0.009), not on ART (n=158, 20%; NNTI=2.1 vs. 4.9; p<0.001), not enrolled in a methadone program (n=604, 77%; NNTI=3.3 vs. 10.4, p<0.001), reporting injecting <5 years (n=441, 56%; NNTI=3.3 vs. 5.0; p=0.005), or from Nairobi (n=452, 58%; NNTI=3.2 vs. 5.6, p<0.001).
Conclusions Scaling up APS among PWID-LWH with certain characteristics could result in more efficient APS and greater partner engagement in HIV care.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03447210
Clinical Protocols
https://doi.org/10.1136/bmjopen-2020-041083
Funding Statement
This study was funded by the U.S. National Institutes of Health National Institute on Drug Abuse (NIDA), award number R01DA043409.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Human Subjects Division of University of Washington gave ethical approval for this work. The Ethics and Research Committee of Kenyatta National Hospital-University of Nairobi gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-Senior Authors.
Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to disclose. This study was funded by the U.S. National Institutes of Health National Institute on Drug Abuse (NIDA), award number R01DA043409. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. NTL was supported by an NIH diversity supplement through NIDA (R01DA043409-S1). LWM and SJM received support from Fogarty International Center (D43TW009580).
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
